Researchers Identify Potential Glioblastoma Weakness for New Therapies

Researchers at The Ohio State University Comprehensive Cancer Center have identified the SET protein as a potential target to overcome glioblastoma's resistance to current treatments. Preclinical experiments showed that blocking SET prevented tumor formation and made cancer cells more vulnerable to radiation by restoring PP2A enzyme activity. This discovery offers a new approach to improve therapies for this aggressive brain cancer, though human testing is required to confirm safety and efficacy.